RENAL-FUNCTION IN PREMATURE-INFANTS DURING AMINOGLYCOSIDE THERAPY

被引：25

作者：

GIAPROS, VI ^{[1
]}

ANDRONIKOU, S ^{[1
]}

CHOLEVAS, VI ^{[1
]}

PAPADOPOULOU, ZL ^{[1
]}

机构：

[1] UNIV IOANNINA,SCH MED,DEPT PAEDIAT,GR-45110 IOANNINA,GREECE

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 02期

关键词：

PREMATURITY; AMINOGLYCOSIDE TOXICITY; RENAL TUBULAR DYSFUNCTION;

D O I：

10.1007/BF00860733

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The effect of three different aminoglycosides on renal function was evaluated in 30 premature infants of similar gestational age who were treated within 24 h of birth with either amikacin (10 infants, group A), gentamicin (10 infants, group B) or netilmicin (10 infants, group C), for a period of 7 days. Ten infection-free premature infants of similar post-conceptional age were used as controls. Serial determinations of plasma creatinine concentration (PCr), as well as the fractional excretion of sodium (FENa), potassium, magnesium (FEMg), phosphate (FEP) and uric acid (FEUA), and the urinary excretion of calcium (UCa/UCr ratio) were assessed before, during and after treatment. During the treatment period a significant increase in FENa, FEMg and UCa/UCr was observed in group B (P < 0.05 and P < 0.01, respectively) and an increase in FENa and UCa/UCr in group C (P < 0.01) compared with controls. These disturbances were observed with trough concentrations of aminoglycosides but were accentuated at peak serum concentrations and were restored to normal 2 days after stopping therapy. In addition, a significant correlation was demonstrated between FENa, FEMg and UCa/UCr ratio in treated patients. PCr levels decreased similarly in all patient groups, but in 8 of 30 infants (27%) they remained elevated and returned to control values only 10 days after stopping therapy. Such renal functional disturbances, although transient, may result in significant electrolyte and mineral imbalance in the sick premature infant.

引用

页码：163 / 166

页数：4

共 21 条

[1]

Itsarayoungyuen S., Riff L., Scauf V., Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function, Pediatr Pharmacol, 2, pp. 143-145, (1982)

[2]

Rajchot P., Prober C., Soldin S., Perlman M., Good F., Harding E., Klein J., Macleod S., Aminoglycoside-related nephrotoxicity in the premature newborn, Clinical Pharmacology and Therapeutics, 35, pp. 394-401, (1984)

[3]

Aujard Y., Biou A., Coache M., Demelier J., Gouyon J.B., Jacqz E., Mathieu H., Nephrotoxicity of gentamicin and netilmicin in neonates. A comparative study using tubular markers, Dev Pharmacol Ther, 10, pp. 145-152, (1987)

[4]

Tessin I., Bergmark J., Hiesche K., Jagenburg R., Trollfors B., Renal function of neonates during gentamicin treatment, Arch Dis Child, 57, pp. 758-760, (1982)

[5]

Elinder G., Aperia A., Development of glomerular filtration rate and excretion of β2-microglobulin in neonates during gentamicin treatment, Acta Paediatr Scand, 72, pp. 219-224, (1983)

[6]

Rothberg A., Andronikou S., Effect of tobramycin on fractional sodium excretion in neonates, Pediatr Pharmacol, 4, pp. 49-52, (1984)

[7]

Landers S., Berry P.L., Kearns G.L., Kaplan S.L., Rudolph A.J., Gentamicin disposition and effect on development of renal function in the very low birth weight infant, Dev Pharmacol Ther, 7, pp. 285-302, (1984)

[8]

Adelman R.D., Halsted C.C., Jordan G.W., Russo J., Use of urinary enzyme activities in the early detection of aminoglycoside nephrotoxicity. A study in children and adults receiving gentamicin or netilmicin, Proc West Pharmacol Soc, 24, pp. 261-264, (1981)

[9]

Adelman R.D., Wirth F., Rubio T., A controlled study of nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate, J Pediatr, 111, pp. 888-893, (1987)

[10]

Dubowitz L.M., Dubowitz V., Goldberg C., Clinical assessment of gestational age in the newborn infant, J Pediatr, 77, pp. 1-10, (1970)

← 1 2 3 →